ABT-700 + erlotinib

ABT-700 + erlotinib is an investigational combination therapy comprising **ABT-700**, a bivalent humanized IgG1 monoclonal antibody targeting the c-Met receptor, and **erlotinib**, a small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. ABT-700 binds cellular c-Met, disrupting both ligand-dependent and ligand-independent (amplification-driven) c-Met activation, leading to inhibition of downstream oncogenic signaling and induction of apoptosis in tumor cells harboring MET amplification or overexpression. Erlotinib selectively inhibits the tyrosine kinase activity of EGFR, a well-established driver mutation in several cancers, notably non-small cell lung cancer (NSCLC). The rationale for this combination is based on evidence that c-Met and EGFR pathways can both drive tumorigenesis and resistance, particularly in NSCLC and certain gastrointestinal cancers. As a combination, these agents are hypothesized to provide synergistic antitumor responses by co-inhibiting parallel pathways implicated in acquired resistance to EGFR inhibition[1][3][5]. ABT-700 is developed by AbbVie; erlotinib is developed and manufactured by Roche/Genentech. Clinical evaluation has primarily focused on solid tumors with MET amplification and/or EGFR mutation/overexpression[1][3].

Brand names

Tarceva

Other names

ABT-700 + Tarceva